|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
64728720X |
| 003 |
DE-627 |
| 005 |
20230905072344.0 |
| 007 |
tu |
| 008 |
110223s2011 xxu||||| 00| ||eng c |
| 010 |
|
|
|a 2011002984
|
| 020 |
|
|
|a 9780470566664
|c cloth
|9 978-0-470-56666-4
|
| 035 |
|
|
|a (DE-627)64728720X
|
| 035 |
|
|
|a (DE-599)GBV64728720X
|
| 035 |
|
|
|a (OCoLC)837944525
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XD-US
|
| 050 |
|
0 |
|a QR186.7
|
| 060 |
|
0 |
|a QW 575
|
| 082 |
0 |
|
|a 616.07/98
|q LOC
|2 22
|
| 084 |
|
|
|a 15,3
|2 ssgn
|
| 084 |
|
|
|a 44.38
|2 bkl
|
| 084 |
|
|
|a 44.45
|2 bkl
|
| 245 |
1 |
0 |
|a Detection and quantification of antibodies to biopharmaceuticals
|b practical and applied considerations
|c ed. by Michael G. Tovey
|
| 264 |
|
1 |
|a Hoboken, NJ
|b Wiley
|c 2011
|
| 300 |
|
|
|a XXIII, 404, [12] S.
|b graph. Darst.
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Literaturangaben
|
| 505 |
8 |
0 |
|t The use of surface plasmon resonance for the detection and characterization of antibodies
|r Steven J. Swanson and Daniel Mytych
|
| 505 |
8 |
0 |
|t Principals of risk assessment and monitoring of antibody responses to biopharmaceuticals
|r Eugen Koren, Erik Foehr, and Charles A. O'Neill
|
| 505 |
8 |
0 |
|t Hypersensitivity reactions to biopharmaceuticals : detection and quantification of drug-specific IgE antibodies
|r Jørgen Dahlstrøm and Lennart Venemalm
|
| 505 |
8 |
0 |
|t Standardization and validation of immunoassays and biophysical assays for the detection of anti-drug antibodies
|r Daniel Kramer
|
| 505 |
8 |
0 |
|t Standardization and validation of cell-based assays for the detection of neutralizing anti-drug antibodies
|r Deborah Finco-Kent and Amy Grenham
|
| 505 |
8 |
0 |
|t Standardization of neutralizing antibody unitge by bioassay design : constant antigen and constant antibody methodology
|r Sidney E. Grossberg, Yoshimi Kawade, and Leslie D. Grossberg
|
| 505 |
8 |
0 |
|t Cut-points and performance characteristics for anti-drug antibody assays
|r Viswanath Devanarayan and Michael G. Tovey
|
| 505 |
8 |
0 |
|t Dilutional linearity for neutralizing antibody assays
|r David Lansky and Carrie Wager
|
| 505 |
8 |
0 |
|t Detection of neutralizing antibodies to biopharmaceuticals in the presence of high levels of circulating drug
|r Arno Kromminga and Michael G. Tovey.
|
| 505 |
8 |
0 |
|t Immunogenicity of therapeutic proteins : a regulatory perspective
|r Susan Kirshner
|
| 505 |
8 |
0 |
|t Guidance on immunogenicity assessment of biologically-derived therapeutic proteins : an European perspective
|r Meenu Wadhwa and Robin Thorpe
|
| 505 |
8 |
0 |
|t Japanese regulatory perspective on immunogenicity
|r Takao Hayakawa and Akiko Ishii
|
| 505 |
8 |
0 |
|t Enzyme immunoassays and radioimmune assays for quantification of anti-TNF biopharmaceuticals and anti-drug antibodies
|r Klaus Bendtzen and Morten Svenson
|
| 505 |
8 |
0 |
|t Confirmatory immunogenicity assays
|r Eric Wakshull and Daniel Coleman
|
| 505 |
8 |
0 |
|t The use of pharmacodynamics as a surrogate marker for the detection of anti-drug neutralizing antibodies
|r Florian Deisenhammer
|
| 505 |
8 |
0 |
|t Cell-based assays for the detection of neutralizing antibodies to interferon beta (IFN-?) and tumor necrosis factor-alpha (TNF-?) inhibitors
|r Anthony Meager
|
| 505 |
8 |
0 |
|t Detection of neutralizing antibodies (NABs) to Interferon-beta by real time RT-PCR
|r Francesca Gilli and Antonio Bertolotto
|
| 505 |
8 |
0 |
|t Competitive ligand binding assays for the detection of neutralizing antibodies
|r Bonnie Wu, George R. Gunn III, and Gopi Shankar
|
| 650 |
|
0 |
|a Immunoglobulins
|x Analysis
|
| 650 |
|
0 |
|a Immunoassay
|
| 650 |
|
2 |
|a Antibodies, Neutralizing
|x analysis
|
| 650 |
|
2 |
|a Antibodies, Neutralizing
|x immunology
|
| 650 |
|
2 |
|a Biological Products
|x immunology
|
| 650 |
|
2 |
|a Immunoassay
|x methods
|
| 689 |
0 |
0 |
|D s
|0 (DE-588)7689632-8
|0 (DE-627)618407677
|0 (DE-576)318506688
|a Biologika
|2 gnd
|
| 689 |
0 |
1 |
|D s
|0 (DE-588)4002290-0
|0 (DE-627)106393898
|0 (DE-576)208846433
|a Antikörper
|2 gnd
|
| 689 |
0 |
2 |
|D s
|0 (DE-588)4661099-6
|0 (DE-627)337550468
|0 (DE-576)214771482
|a Neutralisierung
|g Immunologie
|2 gnd
|
| 689 |
0 |
|
|5 (DE-627)
|
| 700 |
1 |
|
|a Tovey, Michael G.
|4 oth
|
| 776 |
1 |
|
|z 9781118075685
|c (oBook)
|
| 776 |
1 |
|
|z 9781118075661
|c (ePDF)
|
| 776 |
1 |
|
|z 9781118075678
|c (ePub)
|
| 856 |
4 |
2 |
|u http://www.gbv.de/dms/bs/toc/64728720X.pdf
|m V:DE-601
|m B:DE-84
|q pdf/application
|v 2011-10-24
|x Verlag
|y Inhaltsverzeichnis
|3 Inhaltsverzeichnis
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a ISIL_DE-84
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a SSG-OPC-DE-84
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a ISIL_DE-9
|
| 936 |
b |
k |
|a 44.38
|j Pharmakologie
|0 (DE-627)106409743
|
| 936 |
b |
k |
|a 44.45
|j Immunologie
|0 (DE-627)106409689
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 616.07/98
|
| 980 |
|
|
|2 20
|1 01
|x 0084
|b 1246989522
|c 00
|f --%%--
|d 2916-0044
|e --%%--
|j --%%--
|y k
|z 30-09-11
|
| 980 |
|
|
|2 69
|1 01
|x 0009
|b 1271648709
|c 00
|f UB 660
|d 660/VX 8500 T736
|e u
|j --%%--
|y z
|z 24-01-12
|
| 984 |
|
|
|2 20
|1 01
|x 0084
|a 84$029160044
|
| 984 |
|
|
|2 69
|1 01
|x 0009
|a 9$09061657
|
| 985 |
|
|
|2 69
|1 01
|x 0009
|a 2011.11866
|
